• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • 2MM Podcast
  • Write for us
  • Contact Us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • About
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Tools+
    • EvidencePulse™
    • HypeCheck™
    • NPI Registry Lookup
    • RVU Search
  • Pharma
  • AI Roundup
  • The Scan+
  • Classics™+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • My account
    • Cart
    • Sign in
2 Minute Medicine
  • About
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Tools+
    • EvidencePulse™
    • HypeCheck™
    • NPI Registry Lookup
    • RVU Search
  • Pharma
  • AI Roundup
  • The Scan+
  • Classics™+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • My account
    • Cart
    • Sign in
SUBSCRIBE
2 Minute Medicine
Subscribe
EvidencePulse™ by 2 Minute Medicine 2026 evidence scan 3 reports You asked top stroke trials 2026 Synthesizing medical evidence... Top 2026 stroke trial results: OCEANIC — ischemic stroke: 6.2% vs 8.4% OPTION* — mRS 0–1: 43.6% vs 34.2% ORIENTAL* — mRS 0–2: 58.6% vs 46.6% *Higher sICH in intervention arms Participants randomizedN OCEANIC 12,327 OPTION 570 ORIENTAL 564 Ask about guidelines or landmark trials... ↑ Try EvidencePulse™ Ask the evidence.
Get the signal.
Try it now → Physician-trained medical AI by 2 Minute Medicine
Home All Specialties Chronic Disease

Increased gut inflammation is associated with greater structural spinal damage in axial spondyloarthritis

byAlex XiangandSimon Pan
January 13, 2026
in Chronic Disease, Gastroenterology, Rheumatology
Reading Time: 2 mins read
Traumatic spinal cord injury rates remain stable in the United States
Share on FacebookShare on Twitter

1. Increased gut inflammation, as measured by fecal calprotectin, is significantly associated with greater structural spinal damage in axial spondyloarthritis

Evidence Rating Level: 2 (Good)

A significant proportion of patients with axSpA have comorbid inflammatory bowel disease (IBD) or elevated inflammation, measured histologically and through fecal calprotectin. Prior studies have identified a link between the degree of inflammation and more active disease in axSpA. However, it is unknown whether gut inflammation is also associated with more structural spinal damage in axSpA. This cross-sectional analysis of the SPARTAKUS cohort analyzed 228 patients (mean age ± SD, 51.0 ± 13.0; 53% male) with well-established non-radiographic or radiographic axSpA. axSpA Patients were stratified by fecal calprotectin levels (< 50 mg/kg, 50-149 mg/kg, and ≥ 150 mg/kg). There was significantly higher structural spinal damage, measured with the modified Stoke ankylosing spondylitis spinal score (mSASSS) in the fecal calprotectin > 50 mg/kg group compared to the fecal calprotectin < 50 mg/kg group (OR 95% CI, 2.17 (1.24-3.80), p = 0.007). This relationship remained after removing IBD patients from analysis (OR 95% CI, 2.48 (1.36-4.53), p = 0.003). Overall, this study suggests the degree of gut inflammation is a good prognostic indicator of spinal radiographic progression in axSpA. However, prospective studies are required to elucidate causality.

Click here to read this study in Arthritis Research & Therapy

Image: PD

©2025 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

RELATED REPORTS

The addition of leflunomide (Arava) to prednisone (Deltasone) may not improve rate of remission in Takayasu arteritis

2 Minute Medicine Rewind July 6, 2026

Guselkumab (Tremfya) strengthens its case for protecting joints in psoriatic arthritis

Tags: axial spondyloarthritisfecal calprotectingut inflammationinflammatory bowel disease (IBD)rheumatology
Previous Post

Mediterranean diet may be effective for managing IBS

Next Post

2 Minute Medicine: Pharma Roundup – Breakthrough ALS gene therapy, new adult pneumonia vaccine, needle-free obesity treatment, and Pfizer’s business overhaul [October 28, 2025]

RelatedReports

Lower target oxygen saturation in extremely preterm infants appears safe
Chronic Disease

The addition of leflunomide (Arava) to prednisone (Deltasone) may not improve rate of remission in Takayasu arteritis

July 10, 2026
Obstetric scoring systems overestimate cases of severe sepsis
All Specialties

2 Minute Medicine Rewind July 6, 2026

July 7, 2026
Brodalumab effective in treating active psoriatic arthritis
Chronic Disease

Guselkumab (Tremfya) strengthens its case for protecting joints in psoriatic arthritis

June 5, 2026
Placebo formulation impacts effectiveness of pain control in osteoarthritis
Imaging and Intervention

Infrapatellar fat pad glucocorticoid injections may not reduce pain or effusion volume in patients with knee osteoarthritis

January 12, 2026
Next Post
2 Minute Medicine: Pharma Roundup: Price Hikes, Breakthrough Approvals, Legal Showdowns, Biotech Expansion, and Europe’s Pricing Debate [May 12nd, 2025]

2 Minute Medicine: Pharma Roundup – Breakthrough ALS gene therapy, new adult pneumonia vaccine, needle-free obesity treatment, and Pfizer’s business overhaul [October 28, 2025]

Gastric bypass surgery reduces cardio-metabolic risk factors

Endoscopic sinus surgery improves quality of life compared with clarithromycin and placebo in chronic rhinosinusitis

Quick Take: Functional Outcome of Intravenous Thrombolysis in Patients With Lacunar Infarcts in the WAKE-UP Trial

Screening for acute ischemic stroke using the Los Angeles Motor Scale may be feasible and improve time to imaging

EvidencePulse™ by 2 Minute Medicine 2026 evidence scan 3 reports You asked top stroke trials 2026 Synthesizing medical evidence... Top 2026 stroke trial results: OCEANIC — ischemic stroke: 6.2% vs 8.4% OPTION* — mRS 0–1: 43.6% vs 34.2% ORIENTAL* — mRS 0–2: 58.6% vs 46.6% *Higher sICH in intervention arms Participants randomizedN OCEANIC 12,327 OPTION 570 ORIENTAL 564 Ask about guidelines or landmark trials... ↑ Try EvidencePulse™ Get the signal. Try it now → Physician-trained medical AI by 2 Minute Medicine

2MM+ All Access

Full details →
$4.99 /month

3-day free trial · cancel anytime

  • ✓100+ physician-written reports
  • ✓EvidencePulse™ + HypeCheck™
  • ✓Ad-free reading + newsletters
Start 3-day free trial

Then $4.99/month. Manage renewal in your account.

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Male sex is associated with higher mortality among patients with hepatocellular carcinoma
  • Artificial intelligence (AI)-supported symptom self-assessment led to more appropriate patient care-seeking decisions
  • Rimegepant (Nurtec ODT) may be an effective alternative to triptans for symptom relief in migraines
License Content
Terms of Use | Disclaimer
Cookie Policy
Cleantalk Pixel
2MM+ All Access Full details →

The medical literature, distilled daily.

Monthly plan selected: $4.99 /month.

$4.99/month

3-day free trial · cancel anytime

Start 3-day free trial

Then $4.99/month. Manage renewal in your account.

Yearly plan selected: $49.90 /year.

$49.90/year

2 months free

Start 3-day free trial

Then $49.90/year.

Membership benefits

  • ✓100+ physician-written reports
  • ✓AI EvidencePulse™ + HypeCheck™
  • ✓Ad-free reading + newsletters

Already a member? Sign in

  • About
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Tools
    • EvidencePulse™
    • HypeCheck™
    • NPI Registry Lookup
    • RVU Search
  • Pharma
  • AI Roundup
  • The Scan
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • My account
    • Cart
    • Sign in
No Result
View All Result

© 2026 2 Minute Medicine, Inc. - Physician-written medical news.